Send to

Choose Destination
N Engl J Med. 2015 Jul 16;373(3):209-19. doi: 10.1056/NEJMoa1505270. Epub 2015 Jun 1.

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

Collaborators (152)

Turner N, André F, Cristofanilli M, Glück S, Harbeck N, Iwata H, Loi S, Loibl S, Verma S, Vermorken JB, Seidman AD, Emerson SS, Antill Y, Harvey S, Harris M, Ganju V, Oakman C, Redfern A, Slancar M, Khasraw M, Cronk M, Lombard J, Dirix L, Canon J-, Confente C, Wynendaele W, Neven P, Vuylsteke P, Baurain J-, Duck L, Forget F, Awada A, Dopchie C, Verma S, Bin J, Li I, Verma S, Elser C, Miller W, Findlay B, Martin LA, Ellard S, Freedman O, Loibl S, Forstmeyer D, Harbeck N, Murphy C, Soto Parra H, Zamagni C, Colleoni M, Barone C, De Laurentis M, Gianni L, Roila F, Amadori D, Inoue K, Iwata H, Mukai H, Masuda N, Rai Y, Hara F, Ishida M, Nakamura R, Kim S-, Ro J, Im S-, Im Y-, Kim JH, Kroep J, Portielje J, de Jongh F, van Alphen R, Erdkamp F, de Boer M, Cardoso F, Bordalo e Sa J, Toganel C, Ganea DE, Crihana C, Turcu A, Vladimirov V, Lipatov O, Komov D, Fadeeva N, Krasnozhon D, Chang T-, Gokmen E, Shevnia S, Berzoy O, Shparyk Y, Hontsa A, Vinnyk Y, Archer C, Turner N, Coleman R, Barrett-Lee P, Henderson C, Kalmadi S, Wilkinson M, Goldberg J, Tiber C, Beeker T, Kabos P, O'Rourke T, Link J, Citron M, Margileth D, DeMichele A, Helsten T, Stearns V, Vaklavas C, Sleckman B, Dillon P, Hetzel D, Niu J, Dichmann R, Lawler W, DiCarlo B, Calfa C, Chan D, Allison MA, Jones C, Waisman J, Krill-Jackson E, Mahtani R, Potter D, Burness M, Caballero Monge AG, Huggines-Puhalla S, Slamon D, Beck A, Toppmeyer D, Rao R, Patel R, Jaslow R, Weisberg T, Chalasani P, Rakkar AN, Lashkari A, Adoo C, McIntyre K, Houck W 3rd, Vukelja S, Wilks S, Restrepo A, Rugo H, Danso M, Robert N, Hermann R, Lindquist D, Ellis E, Moroose R.

Author information

From Royal Marsden Hospital, London (N.C.T.); National Cancer Center, Goyang-si, South Korea (J.R.); Institut Gustave Roussy, Villejuif, France (F.A.); Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia (S. Loi); Sunnybrook Odette Cancer Centre, Toronto (S.V.); Aichi Cancer Center Hospital, Nagoya, Japan (H.I.); Brustzentrum der Universität München, Munich (N.H.), and German Breast Group Forschungs, Neu-Isenburg (S. Loibl) - both in Germany; Pfizer, New York (C.H.B., M.K.), La Jolla, CA (K.Z., S.R.), and Milan (C.G.); and Thomas Jefferson University, Philadelphia (M.C.).



Growth of hormone-receptor-positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase to the S phase of the cell cycle. We assessed the efficacy of palbociclib (an inhibitor of CDK4 and CDK6) and fulvestrant in advanced breast cancer.


This phase 3 study involved 521 patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that had relapsed or progressed during prior endocrine therapy. We randomly assigned patients in a 2:1 ratio to receive palbociclib and fulvestrant or placebo and fulvestrant. Premenopausal or perimenopausal women also received goserelin. The primary end point was investigator-assessed progression-free survival. Secondary end points included overall survival, objective response, rate of clinical benefit, patient-reported outcomes, and safety. A preplanned interim analysis was performed by an independent data and safety monitoring committee after 195 events of disease progression or death had occurred.


The median progression-free survival was 9.2 months (95% confidence interval [CI], 7.5 to not estimable) with palbociclib-fulvestrant and 3.8 months (95% CI, 3.5 to 5.5) with placebo-fulvestrant (hazard ratio for disease progression or death, 0.42; 95% CI, 0.32 to 0.56; P<0.001). The most common grade 3 or 4 adverse events in the palbociclib-fulvestrant group were neutropenia (62.0%, vs. 0.6% in the placebo-fulvestrant group), leukopenia (25.2% vs. 0.6%), anemia (2.6% vs. 1.7%), thrombocytopenia (2.3% vs. 0%), and fatigue (2.0% vs. 1.2%). Febrile neutropenia was reported in 0.6% of palbociclib-treated patients and 0.6% of placebo-treated patients. The rate of discontinuation due to adverse events was 2.6% with palbociclib and 1.7% with placebo.


Among patients with hormone-receptor-positive metastatic breast cancer who had progression of disease during prior endocrine therapy, palbociclib combined with fulvestrant resulted in longer progression-free survival than fulvestrant alone. (Funded by Pfizer; PALOMA3 number, NCT01942135.).

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center